Shares of Evoke Pharma, Inc. (NASDAQ:EVOK – Get Free Report) passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $5.74 and traded as low as $4.73. Evoke Pharma shares last traded at $4.95, with a volume of 38,468 shares traded.
Analyst Ratings Changes
Separately, StockNews.com began coverage on Evoke Pharma in a research note on Thursday. They set a “sell” rating for the company.
Evoke Pharma Stock Up 1.6 %
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). Evoke Pharma had a negative return on equity of 964.25% and a negative net margin of 86.74%. The business had revenue of $2.55 million during the quarter.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Recommended Stories
- Five stocks we like better than Evoke Pharma
- Stock Dividend Cuts Happen Are You Ready?
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- High Flyers: 3 Natural Gas Stocks for March 2022
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- What is Short Interest? How to Use It
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.